AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Resectable Non-small Cell Lung Cancer Clinical Trial

Official title:
Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer

Status Not yet recruiting

Clinical Trial Summary

AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC

Clinical Trial Description

Phase II clinical study of AK112, an anti-PD-1 and VEGF bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Resectable Non-small Cell Lung Cancer

Clinical Trial Details

NCT number	NCT05247684
Study type	Interventional
Source	Akeso
Contact	Weifeng Song, MD
Phone	86(0760)89873999
Email	clinicaltrials@akesobio.com
Status	Not yet recruiting
Phase	Phase 2
Start date	February 20, 2022
Completion date	January 20, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06169956` - An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany
Recruiting	`NCT05472623` - Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab	Phase 2
Recruiting	`NCT06161441` - A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery	Phase 2
Completed	`NCT02053220` - Mechanism of Action Trial of ColoAd1	Phase 1